Pear Therapeutics gets court approval of four asset sales

By Sarah Lizee

Olympia, Wash., May 23 – Pear Therapeutics, Inc. received approval to sell four sets of assets following an auction held Thursday and a sale hearing on Monday, according to orders filed with the U.S. Bankruptcy Court for the District of Delaware.

As previously reported, Click Therapeutics, Inc. was selected as the successful bidder for the debtors’ assets related to all Pear platform patents, excluding patents related to the invention science fund assets.

Click agreed to purchase the Pear platform assets for $70,000 in cash.

Harvest Bio LLC was selected as the successful bidder for the debtors’ assets related to the invention science fund licenses and patents, schizophrenia assets, multiple sclerosis and depression assets, major depressive disorder assets, other pipeline assets, corporate trademarks, PearConnect assets and reSET assets.

Harvest’s agreed to purchase the assets for a total of $2.03 million in cash.

Nox Health Group, Inc. was selected as the successful bidder for the debtors’ assets related to Somryst. Nox agreed to purchase the Somryst assets for a purchase price of $3.9 million in cash.

WELT Corp. Ltd. was selected as the successful bidder for the debtors’ migraine assets. WELT agreed to purchase the migraine assets for a purchase price of $50,000 in cash.

Boston-based Pear Therapeutics develops and commercializes software-based medicines called prescription digital therapeutics. The company filed bankruptcy on April 7 under Chapter 11 case number 23-10429.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.